marked.bio

Company

AbbVie

8 active trials that select patients by a biomarker on marked.bio, across 5 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

telisotuzumab adizutecan 3osimertinib 3budigalimab 2venetoclax 1bevacizumab 1nivolumab 1telisotuzumab vedotin 1erlotinib 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

8 of 20 trials shown

  1. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2036-11 NCT07005102

    telisotuzumab adizutecanosimertinib FDA EUcisplatincarboplatinpemetrexed

    …d metastatic/locally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by…

    EGFR exon 19 deletion / L858RNon-Squamous Non-Small Cell Lung Cancer, c-MET

  2. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2030-09 NCT07155187

    telisotuzumab adizutecanosimertinib FDA EU

    …vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer, c-MET

  3. A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

    Active, not recruiting Phase 2 AbbVie Started 2024Primary completion 2027-02 NCT06365853

    Mirvetuximab SoravtansineLubricating Eye DropsprednisoneBrimonidine tartrate ophthalmic solution eye drops

    Participants with known breast cancer susceptibility gene (BRCA) mutations (tumor or germline) must have received poly (ADP-ribose) polymerase inhibitors (PARPi).

    BRCA1/2 mutationRecurrent Ovarian Cancer, Folate Receptor-Alpha Positive

  4. Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

    Active, not recruiting Phase 2 AbbVie Started 2022Primary completion 2026-11 NCT05456685

    Mirvetuximab soravtansinecarboplatin

    Somatic and germline BRCA-positive participants must have received prior treatment with a poly adenosine phosphate-ribose po…

    BRCA1/2 mutationHigh Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

  5. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    Active, not recruiting Phase 1 AbbVie Started 2023Primary completion 2031-03 NCT05753501

    ABBV-101venetoclax

    … primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 re…

    ALK fusionHematologic Cancer

  6. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

    Active, not recruiting Phase 1 AbbVie Started 2022Primary completion 2027-11 NCT05599984

    ABBV-706cisplatinbudigalimabcarboplatin

    …euroendocrine carcinoma (LCNEC)s, SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), atypical lung carcinoids, and other high-grade poorly…

    EGFR exon 19 deletion / L858RIDH1/2 mutationAdvanced Solid Tumors

  7. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Recruiting Phase 1 AbbVie Started 2021Primary completion 2027-07 NCT05005403

    Azirkitugbudigalimabbevacizumabtelisotuzumab adizutecan

    …essed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Rego…

    BRAF V600ENon-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer

  8. A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

    Active, not recruiting Phase 1 AbbVie Started 2014Primary completion 2026-08 NCT02099058

    osimertinib FDA EUnivolumabtelisotuzumab vedotinerlotinib FDA EU

    …ced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resi…

    EGFR exon 19 deletion / L858RAdvanced Solid Tumors Cancer